Alnylam gets good news on RNAi treatment; Northwestern looks at getting nanotech into cancer nuclei;

 @DamianFierce: Using self-assembling DNA tubes, Harvard researchers plan to effectively deliver drugs to cells. News | Follow @DamianFierce

> Alnylam ($ALNY) is reporting positive Phase I results for its RNAi therapy designed to treat transthyretin-mediated amyloidoisis. Release

> A NeuroSigma subsidiary, NSVascular, has bought the patents for thin-film nitinol fabrication with an eye on its drug delivery applications. News

> Getting nanocarriers to tumors is one thing; getting them inside to deliver their payloads is another. Researchers at Northwestern University are working to get nanoparticles into the nuclei of cancer cells. Article

> Pearl Therapeutics is preparing to present positive Phase II results for PT003, a novel-formulation COPD treatment. Story

> Pulmatrix has revealed the results of preclinical tests on iSperse, an inhaled drug delivery platform that demonstrated its ability to deliver antibiotics, antibodies and other macromolecules. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.